Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as ... - PR Newswire

Retrieved on: 2023-11-04 15:17:54

Tags for this article:

Lung cancer

KRAS

Non-small-cell lung cancer

Adenocarcinoma of the lung

Treatment of lung cancer

Mirati Therapeutics Inc.

Click the tags to see associated articles and topics

Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as ... - PR Newswire. View article details on HISWAI: https://www.prnewswire.com/news-releases/mirati-therapeutics-receives-approval-from-the-mhra-for-krazati-adagrasib-as-a-targeted-treatment-option-for-patients-with-advanced-non-small-cell-lung-cancer-nsclc-with-a-krasg12c-mutation-301977569.html

Excerpt

Mirati Contacts. Investor Relations: ir@mirati.com. Media Relations: media@mirati.com. References. 1 ... Products. For Marketers · For Public Relations ...

Article found on: www.prnewswire.com

View Original Article